U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07096128) titled 'A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer' on July 21.
Brief Summary: This was a multicenter, open-label, phase I study to evaluate the safety, tolerability, radiation dosimetry and efficacy of [177Lu] Lu-PSMA-XT injection in patients with metastatic prostate cancer .
Study Start Date: Aug. 20, 2024
Study Type: INTERVENTIONAL
Condition:
mCRPC
Intervention:
DRUG: [177Lu]Lu-PSMA-XT
[177Lu]Lu-PSMA-XT is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells.
Recruitment Status: RECRUITING
Sponsor: Jinming Zhang
Information provided by (Responsible Party): ...